Tommy Leggett

Chief Financial Officer


Tommy Leggett is chief financial officer (CFO) of Stoke Therapeutics. In this role, he oversees all aspects of the company’s financial strategy and operations.

Tommy has more than 20 years of experience as a biotechnology executive, board member and as an investment banker. He has led financial strategy and operations and secured financing for dozens of life science companies. Prior to joining Stoke, Tommy served as CFO of Affinia Therapeutics. Before joining Affinia Therapeutics, Tommy was CFO at Black Diamond Therapeutics, where he led the company’s Series C financing and initial public offering (IPO). Prior to Black Diamond, he served as CFO at Axcella Health, where he helped raise capital across three financings, including an IPO. Before joining the biotechnology industry, Tommy spent more than a decade as an investment banker for the healthcare groups at J.P. Morgan Securities, Lazard Frères & Company, and UBS Securities. Tommy currently serves on the board of directors of Clover Biopharmaceuticals, Ltd.

Tommy received a B.A. in economics from Columbia University and an M.B.A. in finance from the Wharton School at the University of Pennsylvania.